Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

WIB_icon

Is NCCN-IPI a Better Prognostic Tool for DLBCL Treated With R-CHOP?

Compared with the widely used International Prognostic Index (IPI) and revised IPI (R-IPI), the most recent National Comprehensive Cancer Network IPI (NCCN-IPI) better predicts...
On location

KEYNOTE-204: Pembrolizumab Superior to Brentuximab in Relapsed/Refractory Classic Hodgkin Lymphoma

Treatment with anti-PD-1 antibody pembrolizumab prolonged progression-free survival (PFS) more than brentuximab vedotin (BV) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R...
WIB_icon

Temozolomide Demonstrates High Response in Older Patients With Primary Vitreoretinal Lymphoma

Temozolomide demonstrated a high overall response rate in a study of patients with primary vitreoretinal lymphoma (PVRL) who were either considered ineligible for intensive...

Outpatient CAR T-Cell Therapy Appears Feasible for Patients With Large B-Cell Lymphoma

According to an analysis of three studies evaluating lisocabtagene maraleucel (liso-cel) presented at the 2020 Transplantation & Cellular Therapy Meetings, treatment with the outpatient...

FDA Grants Orphan Drug Designations to Avatrombopag and CLR 131

The FDA has granted orphan drug designations to two therapies for hematologic conditions. The oral thrombopoietin receptor agonist avatrombopag is indicated for the treatment of...

Tazemetostat Granted Priority Review for Relapsed/Refractory Follicular Lymphoma

The FDA granted a priority review to the new drug application (NDA) for tazemetostat for the treatment of patients with relapsed or refractory follicular...

CAR T-Cell Therapy KTE-X19 Granted Priority Review for MCL

The FDA granted priority-review designation to the investigational chimeric antigen receptor (CAR) T-cell therapy KTE-X19 for the treatment of adults with relapsed or refractory...
WIB_icon

Avadomide Shows Promising Clinical Activity and Tolerability in Relapsed/Refractory DLBCL

Avadomide monotherapy demonstrated preliminary clinical efficacy in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), according to results from a phase I...

The Year in FDA Approvals

In the past year, the FDA approved a record-breaking number of drugs, several of which were indicated for the treatment of lymphoid and plasma...
On location

Can Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Skip Radiation Therapy?

Results from the Intergroup National Clinical Trials Network (NCTN) study S1001 demonstrated that 89% of patients with limited-stage diffuse large B-cell lymphoma (DLBCL) maintained...